Abstract
Certain embodiments are directed to a new human parainfluenza virus (HPIV)/SARS-CoV-2 vaccine or vaccine construct/polynucleotide. In certain aspects the vaccine or vaccine construct is administered via intranasal administration.
Original language | English (US) |
---|---|
Patent number | WO2023133227A2 |
Filing date | 1/5/23 |
State | Published - Jul 13 2023 |